Project Grant R43HL186956
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bloomington, MN 55437, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Respair, Inc. $305,218 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate AssuranceET, a novel pediatric endotracheal tube with an ultra-soft micro-baffle sealing mechanism designed to replace traditional inflatable balloon cuffs and reduce airway trauma and aspiration risk in mechanically ventilated children. AssuranceET uses thin, flexible disc-shaped micro-baffles that fold...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the Department of Health and Human Services, awarded $307,596 to Et-Trac LLC on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a cost-effective near-infrared (NIR) imaging device for continuous, noninvasive tracking of endotracheal tube position in pediatric patients. The award funds refinement of the NIR-ETT...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded Tele-Stethoscope Inc. $406,367 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop Phase I algorithms and demonstrate technical feasibility for a mobile phone–based diagnostic tool that uses acoustic data to predict clinically significant spirometry and echocardiogram findings. The recipient will develop algorithms for predicting FEV1 percent predicted findings using mobile phone–captured...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University $577,334 on July 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a sensory airway stent for continuous monitoring of airway conditions. The recipient is creating a sensor-integrated airway stent (SAS) equipped with flexible sensors and a wearable magnetic actuation unit designed to monitor stent patency and airway health in the central airway. The innovation addresses central airway...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded Vivamed, Inc. $257,015 on June 15, 2026, to develop a wirelessly powered, battery-free hypoglossal nerve stimulator for treating obstructive sleep apnea under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a minimally invasive implantable device designed to address limitations of existing hypoglossal nerve stimulation systems. The device will integrate electromyography sensors for real-time muscle...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- The National Heart, Lung, and Blood Institute awarded $499,932 to Safebvm Corp. on September 17, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to integrate capnography sensing into the SOTAIR device for standardizing manual ventilation technique and improving patient outcomes. SOTAIR is a lightweight (14 grams), battery-free attachment device compatible with all commercially available bag-valve masks that employs flow-blocking and pressure-control mechanisms to...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...